Bioequivalence Requirements Could Be Reduced By Question-Based Review
Executive Summary
A question-based review emphasizing quality by design could reduce the need to conduct bioequivalence studies for highly variable drugs, FDA said at a meeting of the Advisory Committee for Pharmaceutical Science on May 4